Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gleave

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Cancer Research|March 15, 1992
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factorsM E Gleave, J T Hsieh, H C Wu, et al.
Cancer Research|August 17, 2000
The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxelJ K Jackson, M E Gleave, V Yago, et al.
Cancer Research|June 15, 1993
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) sublineJ T Hsieh, H C Wu, M E Gleave, et al.
British Journal of Urology|March 6, 1998
Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?F Rabbani, S L Goldenberg, M E Gleave, et al.
Seminars in Urologic Oncology|May 1, 1996
Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancerM E Gleave, S L Goldenberg, E C Jones, et al.
International Journal of Cancer|May 1, 1994
Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cellsH C Wu, J T Hsieh, M E Gleave, et al.
Urology|May 1, 1996
Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancerM E Gleave, D Coupland, D Drachenberg, et al.
The Canadian Journal of Urology|July 1, 1995
Venovenous bypass in renal cell carcinoma with caval tumor thrombusD S Ko, C H Scudamore, M E Gleave, et al.
Reviews in Urology|September 21, 2006
Advanced prostate cancer: an updateA Ziada, E D Crawford, F H Schröeder, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2001
Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistryT Zellweger, H Miyake, S Cooper, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Cancer Research|March 15, 1992
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factorsM E Gleave, J T Hsieh, H C Wu, et al.
Cancer Research|August 17, 2000
The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxelJ K Jackson, M E Gleave, V Yago, et al.
Cancer Research|June 15, 1993
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) sublineJ T Hsieh, H C Wu, M E Gleave, et al.
British Journal of Urology|March 6, 1998
Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?F Rabbani, S L Goldenberg, M E Gleave, et al.
Seminars in Urologic Oncology|May 1, 1996
Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancerM E Gleave, S L Goldenberg, E C Jones, et al.
International Journal of Cancer|May 1, 1994
Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cellsH C Wu, J T Hsieh, M E Gleave, et al.
Urology|May 1, 1996
Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancerM E Gleave, D Coupland, D Drachenberg, et al.
The Canadian Journal of Urology|July 1, 1995
Venovenous bypass in renal cell carcinoma with caval tumor thrombusD S Ko, C H Scudamore, M E Gleave, et al.
Reviews in Urology|September 21, 2006
Advanced prostate cancer: an updateA Ziada, E D Crawford, F H Schröeder, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2001
Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistryT Zellweger, H Miyake, S Cooper, et al.
Pageof 9